3-(5-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2,6-dipropylphenoxy)benzyl)-5-(4-(1-methylethoxy)phenyl)-5-methylimidazolidine-2,4-dione | 1198166-26-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(5-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2,6-dipropylphenoxy)benzyl)-5-(4-(1-methylethoxy)phenyl)-5-methylimidazolidine-2,4-dione
• 英文别名: 3-[[3-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)-2,6-dipropylphenoxy]phenyl]methyl]-5-methyl-5-(4-propan-2-yloxyphenyl)imidazolidine-2,4-dione
• CAS: 1198166-26-5
• 化学式: C₃₅H₃₈F₆N₂O₅
• 分子量: 680.688
• InChiKey: DNEQNAKTFSUMLA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.7
• 重原子数：
  48
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  88.1
• 氢给体数：
  2
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  3-(2-iodo-5-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2,6-dipropylphenoxy)benzyl)-5-(4-(1-methylethoxy)phenyl)-5-methylimidazolidine-2,4-dione 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 生成 3-(5-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2,6-dipropylphenoxy)benzyl)-5-(4-(1-methylethoxy)phenyl)-5-methylimidazolidine-2,4-dione
  参考文献：
  名称：

  CARBINOL DERIVATIVES HAVING CYCLIC LINKER

  摘要：

  提供一种新型的LXRβ激动剂，可用作预防和/或治疗动脉粥样硬化；动脉硬化，如糖尿病引起的动脉硬化；血脂异常；高胆固醇血症；与脂质相关的疾病；由炎性细胞因子引起的炎症性疾病；过敏性皮肤病；糖尿病；或阿尔茨海默病的治疗剂。【解决手段】以下一般式（I）所表示的羟甲基化合物或其盐，或其溶剂化合物。

  公开号：

  US20100048610A1

文献信息

• METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS
  申请人：The Rockefeller University

  公开号：EP3402477A2

  公开（公告）日：2018-11-21
• US8153634B2
  申请人：——

  公开号：US8153634B2

  公开（公告）日：2012-04-10
• [EN] TREATMENT AND DIAGNOSIS OF CANCER<br/>[FR] TRAITEMENT ET DIAGNOSTIC DU CANCER
  申请人：RGENIX INC

  公开号：WO2016100619A2

  公开（公告）日：2016-06-23

  This invention features compounds that modulate the activity of liver X receptors, pharmaceutical compositions including the compounds of the invention, and methods of utilizing those compositions for modulating the activity of liver X receptors for the treatment of cancer.
• [EN] METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS<br/>[FR] MÉTHODES POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS À DES CELLULES SUPPRESSIVES DÉRIVÉES DE CELLULES MYÉLOÏDES
  申请人：UNIV ROCKEFELLER

  公开号：WO2017123568A2

  公开（公告）日：2017-07-20

  The invention features methods of treating disorders related to increased levels of myeloid derived suppressor cells such as cancer or infections. The disclosure also provides methods of treating cancer including combinations of LXRβ agonists and immunotherapies such as PD1 inhibitors, PDL1 inhibitors, and adoptive T-cell transfer therapy.
• [EN] METHODS FOR THE TREATMENT OF CANCER<br/>[FR] MÉTHODES POUR LE TRAITEMENT DU CANCER
  申请人：RGENIX INC

  公开号：WO2018222975A1

  公开（公告）日：2018-12-06

  The invention features methods of treating cancer with a combination of an LXRß agonist and GITR modulator. The disclosure also provides methods of treating cancer including combinations of LXRß agonists and GITR modulators with additional immunotherapies such as PD1 inhibitors, PDL1 inhibitors, and adoptive T-cell transfer therapy.